Company: PTPI
Filing Date: 2025-02-10
Form Type: S-1/A
Source: 0001410578-25-000108
Chunk: 168

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-10
Form: S-1/A
Chunk 168
---
 to eliminate the impact of certain items that the Company does not consider indicative of its ongoing operating performance or that are non-recurring in nature. For example, Adjusted EBITDA:

| ● | does not reflect the Company’s capital expenditures, future requirements for capital expenditures or contractual commitments; |

| ● | does not reflect changes in, or cash requirements for, the Company’s working capital needs; |

| ● | does not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on the Company’s debt; and |

| ● | does not reflect payments related to income taxes, if applicable. |

The following table presents a reconciliation of Net loss to Adjusted EBITDA for the years ended December 31, 2023, and 2022.

| ​                                            | ​ 
 ​ | For the Year Ended |             | ​ |   |             | ​ |
|:---------------------------------------------|:--|-------------------:|------------:|:--|:--|------------:|:--|
| ​                                            | ​ |       December 31, |             |   |   |             | ​ |
| ​                                            |   |               2023 |             |   | ​ |        2022 | ​ |
| Net Loss                                     | ​ |                  $ |  -8,163,188 | ​ | $ | -20,037,573 |   |
| Interest income                              | ​ |                  ​ |    -515,311 | ​ | ​ |     -14,194 | ​ |
| Interest expense, promissory note            | ​ |                  ​ |     536,138 | ​ | ​ |     596,018 | ​ |
| Depreciation and amortization expense        | ​ |                  ​ |   3,282,967 | ​ | ​ |   5,598,884 | ​ |
| EBITDA                                       | ​ |                  ​ |  -4,859,394 | ​ | ​ | -13,856,865 | ​ |
| Stock based compensation                     | ​ |                  ​ |     417,230 | ​ | ​ |   1,195,076 | ​ |
| Gain on settlement with Vivus                | ​ |                  ​ |           — | ​ | ​ |  -3,389,941 | ​ |
| Intangible asset impairment                  | ​ |                  ​ |           — | ​ | ​ |   7,460,000 | ​ |
| Change in fair